Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Chylomicronemia from GPIHBP1 autoantibodies

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Expression and one-step purification of active lipoprotein lipase contemplated by biophysical considerations

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ANGPTL4 inactivates lipoprotein lipase by catalyzing the irreversible unfolding of LPL's hydrolase domain

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. The structural basis for monoclonal antibody 5D2 binding to the tryptophan-rich loop of lipoprotein lipase

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Expression and one-step purification of active lipoprotein lipase contemplated by biophysical considerations

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

    Research output: Contribution to journalReviewResearchpeer-review

  3. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis

    Research output: Contribution to journalReviewResearchpeer-review

  4. ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Kazuya Miyashita
  • Jens Lutz
  • Lisa C Hudgins
  • Dana Toib
  • Ambika P Ashraf
  • Wenxin Song
  • Masami Murakami
  • Katsuyuki Nakajima
  • Michael Ploug
  • Loren G Fong
  • Stephen G Young
  • Anne P Beigneux
View graph of relations

Some cases of chylomicronemia are caused by autoantibodies against glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP1), an endothelial cell protein that shuttles LPL to the capillary lumen. GPIHBP1 autoantibodies prevent binding and transport of LPL by GPIHBP1, thereby disrupting the lipolytic processing of triglyceride-rich lipoproteins. Here, we review the "GPIHBP1 autoantibody syndrome" and summarize clinical and laboratory findings in 22 patients. All patients had GPIHBP1 autoantibodies and chylomicronemia, but we did not find a correlation between triglyceride levels and autoantibody levels. Many of the patients had a history of pancreatitis, and most had clinical and/or serological evidence of autoimmune disease. IgA autoantibodies were present in all patients, and IgG4 autoantibodies were present in 19 of 22 patients. Patients with GPIHBP1 autoantibodies had low plasma LPL levels, consistent with impaired delivery of LPL into capillaries. Plasma levels of GPIHBP1, measured with a monoclonal antibody-based ELISA, were very low in 17 patients, reflecting the inability of the ELISA to detect GPIHBP1 in the presence of autoantibodies (immunoassay interference). However, GPIHBP1 levels were very high in five patients, indicating little capacity of their autoantibodies to interfere with the ELISA. Recently, several GPIHBP1 autoantibody syndrome patients were treated successfully with rituximab, resulting in the disappearance of GPIHBP1 autoantibodies and normalization of both plasma triglyceride and LPL levels. The GPIHBP1 autoantibody syndrome should be considered in any patient with newly acquired and unexplained chylomicronemia.

Original languageEnglish
JournalJournal of Lipid Research
Volume61
Issue number11
Pages (from-to)1365-1376
Number of pages12
ISSN0022-2275
DOIs
Publication statusPublished - Nov 2020

Bibliographical note

Copyright © 2020 Miyashita et al.

ID: 61071132